{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-002998","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.695706+00:00","generated_at":"2026-06-06T09:54:53.432840+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Twist Bioscience reports record Q1 revenue of $71.5M (+32% YoY); raises FY2024 guidance to $288M-$293M","bullets":["Orders increased 19% YoY to $77.5M; NGS revenue grew 61% to $39.4M.","Net loss of $43.0M ($0.75 per share) vs. $41.8M ($0.74 per share) in prior year.","Gross margin reached 40.5%, above previous guidance; FY2024 margin guidance raised to 40%-41%.","Appointed Adam Laponis as CFO; expanded Express Genes service to all prep scales.","Cash and investments of $311.1M as of Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-002998","json":"https://secwatch.observer/filing/0001628280-24-002998.json","markdown":"https://secwatch.observer/filing/0001628280-24-002998.md","text":"https://secwatch.observer/filing/0001628280-24-002998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000162828024002998/0001628280-24-002998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000162828024002998/twist-20240202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:54:53.432840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5ba2d4fdcd243830c06e201258ad58ed4666a64","claim":"Twist Bioscience Corp reported the first quarter of fiscal 2024 ended December 31, 2023 results: revenue $71.5 million, net income Net loss attributable to common stockholders for the first quarter of fiscal 2024 was $43.0 million, or $0.75 per share, EPS $0.75 per share. Guidance raised.","evidence_excerpt":"reported financial results and business highlights for the first quarter of fiscal 2024 ended December 31, 2023. \"We're starting fiscal 2024 off strong with record revenue of $71.5 million for the first fiscal quarter, coming in above our projection, with a gross margin of 40.5%,\" said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. \"In SynBio,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828024002998/0001628280-24-002998-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of fiscal 2024 ended December 31, 2023"},{"label":"Revenue","value":"$71.5 million"},{"label":"Net income","value":"Net loss attributable to common stockholders for the first quarter of fiscal 2024 was $43.0 million, or $0.75 per share"},{"label":"EPS","value":"$0.75 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}